Cargando…

The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy

BACKGROUND: Whether combination administration of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and beta-blockers (BBs) has a “reversal” effect on cardiac structure and function for first-diagnosed idiopathic dilated cardiomyopathy (FSIDCM) patients with unc...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Tao, Zhou, Ping, Jiang, Xin, Wang, Na, Shou, Jialing, Fang, Yuqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668220/
https://www.ncbi.nlm.nih.gov/pubmed/38024523
http://dx.doi.org/10.4103/jrms.jrms_626_21
_version_ 1785139417478856704
author Liu, Tao
Zhou, Ping
Jiang, Xin
Wang, Na
Shou, Jialing
Fang, Yuqiang
author_facet Liu, Tao
Zhou, Ping
Jiang, Xin
Wang, Na
Shou, Jialing
Fang, Yuqiang
author_sort Liu, Tao
collection PubMed
description BACKGROUND: Whether combination administration of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and beta-blockers (BBs) has a “reversal” effect on cardiac structure and function for first-diagnosed idiopathic dilated cardiomyopathy (FSIDCM) patients with unclear etiologies and inducements is unknown. MATERIALS AND METHODS: We studied the effect of the protocol on FSIDCM patients. The effect was investigated in 26 FSIDCM patients. The criteria of “complete reversal” included left ventricular end-diastolic diameter (LVEDD) ≤50 mm for females or ≤55 mm for males and left ventricular ejection fraction (LVEF) ≥45%; the criteria of “partial reversal” was the decreased rate of LVEDD (ΔLVEDD) >10% or the increase rate of LVEF (ΔLVEF) >10%; the criteria of “no reversal” included LVEDD >50 mm for females or >55 mm for males and ΔLVEDD <10%, and LVEF <45% and ΔLVEF <10%. RESULTS: Within the follow-up period, nine patients showed “complete reversal,” eight “partial reversal,” and nine “no reversal.” Improvements in echocardiogram parameters were the most significant in “complete reversal” patients (P < 0.001), followed by “partial reversal” and “no reversal” patients (P < 0.05). The QRS (Q wave, R wave, S wave) duration and symptoms duration in “complete reversal” patients were the shortest, followed by “partial reversal” and “no reversal” patients. CONCLUSION: ACEIs or ARBs and BBs have a “complete reversal” effect on the left ventricular size and function of some FSIDCM patients. Patients with a narrow QRS and short symptom duration may have a good response.
format Online
Article
Text
id pubmed-10668220
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-106682202023-08-24 The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy Liu, Tao Zhou, Ping Jiang, Xin Wang, Na Shou, Jialing Fang, Yuqiang J Res Med Sci Original Article BACKGROUND: Whether combination administration of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and beta-blockers (BBs) has a “reversal” effect on cardiac structure and function for first-diagnosed idiopathic dilated cardiomyopathy (FSIDCM) patients with unclear etiologies and inducements is unknown. MATERIALS AND METHODS: We studied the effect of the protocol on FSIDCM patients. The effect was investigated in 26 FSIDCM patients. The criteria of “complete reversal” included left ventricular end-diastolic diameter (LVEDD) ≤50 mm for females or ≤55 mm for males and left ventricular ejection fraction (LVEF) ≥45%; the criteria of “partial reversal” was the decreased rate of LVEDD (ΔLVEDD) >10% or the increase rate of LVEF (ΔLVEF) >10%; the criteria of “no reversal” included LVEDD >50 mm for females or >55 mm for males and ΔLVEDD <10%, and LVEF <45% and ΔLVEF <10%. RESULTS: Within the follow-up period, nine patients showed “complete reversal,” eight “partial reversal,” and nine “no reversal.” Improvements in echocardiogram parameters were the most significant in “complete reversal” patients (P < 0.001), followed by “partial reversal” and “no reversal” patients (P < 0.05). The QRS (Q wave, R wave, S wave) duration and symptoms duration in “complete reversal” patients were the shortest, followed by “partial reversal” and “no reversal” patients. CONCLUSION: ACEIs or ARBs and BBs have a “complete reversal” effect on the left ventricular size and function of some FSIDCM patients. Patients with a narrow QRS and short symptom duration may have a good response. Wolters Kluwer - Medknow 2023-08-24 /pmc/articles/PMC10668220/ /pubmed/38024523 http://dx.doi.org/10.4103/jrms.jrms_626_21 Text en Copyright: © 2023 Journal of Research in Medical Sciences https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Liu, Tao
Zhou, Ping
Jiang, Xin
Wang, Na
Shou, Jialing
Fang, Yuqiang
The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
title The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
title_full The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
title_fullStr The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
title_full_unstemmed The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
title_short The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
title_sort complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668220/
https://www.ncbi.nlm.nih.gov/pubmed/38024523
http://dx.doi.org/10.4103/jrms.jrms_626_21
work_keys_str_mv AT liutao thecompletereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy
AT zhouping thecompletereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy
AT jiangxin thecompletereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy
AT wangna thecompletereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy
AT shoujialing thecompletereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy
AT fangyuqiang thecompletereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy
AT liutao completereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy
AT zhouping completereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy
AT jiangxin completereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy
AT wangna completereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy
AT shoujialing completereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy
AT fangyuqiang completereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy